Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today?

Comments
Loading...
Zinger Key Points
  • Regeneron's Q4 Eylea volumes were impacted by August 2023 launch of Eylea HD and the subsequent patient transitions.
  • The company's Q4 and FY23 revenue increased 14% and 12%, excluding sales from COVID-19 treatment.
  • Discover Fast-Growing Stocks Every Month

Regeneron Pharmaceuticals Inc REGN reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77.

Revenues increased 1% to $3.43 billion, beating the consensus of $3.29 billion. Total revenues excluding Ronapreve (COVID-19 treatment) reached $3.44 billion, up 14% Y/Y.

In the fourth quarter of 2023, Dupixent global net sales (recorded by Sanofi SA SNY) increased 31% Y/Y to $3.22 billion.

Related: Regeneron/Sanofi’s Largest Selling Drug Dupixent Scores FDA Approval For Infants With Esophagus Inflammation.

In the fourth quarter of 2023, U.S. net sales for Eylea HD and Eylea were $1.46 billion, down 2% Y/Y, including $123 million from Eylea HD, due to a lower net selling price and volumes.

Eylea volumes in the fourth quarter of 2023 were impacted by the August 2023 launch of Eylea HD and the subsequent transition of Eylea patients to Eylea HD.

Fourth quarter of 2023, Libtayo sales increased 44% to $244 million.

“We were pleased with our fourth-quarter and full-year 2023 financial performance, highlighted by revenue growth of 14% and 12%, respectively, when excluding contributions from Ronapreve, reflecting continued strength across our business,” said Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron. 

Concurrently, on Friday, the European Medicines Agency accepted for review the marketing application for linvoseltamab for relapsed/refractory multiple myeloma who have progressed after at least three prior therapies

Tuesday, Regeneron formed Regeneron Cell Medicines after 2seventy bio Inc TSVT agreed to sell its oncology and autoimmune research and development programs, clinical manufacturing capabilities, and related platform technologies.

Regeneron will make an upfront payment of $5 million and a single milestone payment.

Around 150 employees from 2seventy bio will transition to Regeneron.

Price Action: REGN shares are up 3.26% at $989.00 during the premarket session on the last check Friday.

Photo via Company

Overview Rating:
Speculative
50%
Technicals Analysis
66
0100
Financials Analysis
40
0100
Overview
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!